Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)

News 27/03/2020

Eight new medicines recommended for approval

EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its March 2020 meeting. In line with EMA’s measures to limit the spread of COVID-19, the meeting was held virtually.

The Committee recommended granting a conditional marketing authorisation for Zolgensma* (onasemnogene abeparvovec), an advanced therapy medicinal product (ATMP) for the treatment of babies and young children with spinal muscular atrophy, a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement. For more information, see the press release in the grid below.

The CHMP adopted a positive opinion for Atectura Breezhaler (indacaterol / mometasone furoate) and Bemrist Breezhaler (indacaterol / mometasone furoate) for the treatment of asthma. These recommendations were adopted by the Committee via written procedure on 2 April 2020.**

The Committee recommended granting a marketing authorisation for Fluad Tetra (influenza vaccine (surface antigen, inactivated, adjuvanted)) for prophylaxis against influenza.

Pretomanid FGK* (pretomanid) received a positive opinion from the CHMP for the treatment of tuberculosis in combination with bedaquiline and linezolid.

The CHMP recommended granting a marketing authorisation for Sarclisa* (isatuximab) for the treatment of multiple myeloma, a cancer of the bone marrow.

Zeposia (ozanimod) received a positive opinion for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease.

The biosimilar medicine Nepexto (etanercept) received a positive opinion for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis, non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

Six recommendations on extensions of therapeutic indication

The Committee recommended extensions of indication for Adcetris, Cosentyx, Intelence, Jorveza, Kineret, and Ruconest.

Outcome of review on direct oral anticoagulants

No change to the conditions of use of the direct oral anticoagulants Eliquis (apixaban), Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban) is needed following a review of the results of a European study of real-world data for these medicines. The study assessed the risk of serious bleeding with these three medicines when used to prevent blood clotting in patients with non-valvular atrial fibrillation (irregular rapid contractions of the heart) and compared this with other oral anticoagulants called vitamin K antagonists.

For more information, see the public health recommendation in the grid below.

Outcome of review on fosfomycin medicines

The Committee recommended that fosfomycin medicines given by infusion (drip) into a vein should only be used to treat serious infections when other antibiotic treatments are not suitable. Fosfomycin medicines given by mouth can continue to be used to treat uncomplicated bladder infections in women and adolescent girls. They can also be used to prevent infection in men undergoing a procedure whereby a tissue sample is taken from their prostate (biopsy).

Fosfomycin medicines given by mouth to children (under 12 years of age) and intramuscular formulations (fosfomycin medicines for injection into a muscle) should no longer be used. These recommendations follow a review of the safety and effectiveness of these antibiotics. For more information, see the public health recommendation in the grid below.

Outcome of review on methocarbamol / paracetamol-containing medicines

The CHMP concluded that the benefits of medicines containing methocarbamol and paracetamol continue to outweigh their risks in the short-term treatment of painful muscle spasms. A review was started as recent publications had raised questions about the effectiveness of the combination of these substances at treating conditions such as low back pain in the doses at which they are present in these medicines.

For more information, see the public health recommendation in the grid below.

Update on nitrosamine impurities – step 1 risk evaluation deadline extended

In consideration of the challenges caused globally to health regulators and industry by the COVID-19 pandemic, the European medicines regulatory network has agreed to extend the deadline for the risk evaluation referred to in the “Information on nitrosamines for marketing authorisation”. Marketing authorisation holders who are currently reviewing their medicines for the possible presence of nitrosamines will now have until 1 October 2020 to submit the results of the step 1 risk evaluation.

For more information on the review, please see our website.

Outcome of review of study data for Tyverb

The product information for Tyverb (lapatinib), a breast cancer medicine, will continue to state that no data are available on the effectiveness of Tyverb used together with an aromatase inhibitor compared with trastuzumab used with an aromatase inhibitor in patients previously treated with trastuzumab. EMA updated the product information for this medicine in April 2019 following detection of errors in results of a study involving postmenopausal women who had ‘HR+/HER2+’.

For more information, see our website.

Withdrawals of applications

The application for an initial marketing authorisation for Doxorubicin Hydrochloride Tillomed (doxorubicin) was withdrawn. This hybrid medicine was intended for the treatment of breast and ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma.

The applications for initial marketing authorisation for two medicines with the active substance rituximab were also withdrawn. These biosimilar medicines were intended for the treatment of certain blood cancers and inflammatory conditions.

Question-and-answer documents on these withdrawals are available in the grid below.

Agenda and minutes

The agenda of the March meeting is published on EMA's website. Minutes of the February 2020 CHMP meeting will be published in the coming weeks.

CHMP statistics

Key figures from the March 2020 CHMP meeting are represented in the graphic below.

* These products were designated as orphan medicines during their development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products (COMP) at the time of approval to determine whether the information available to date allows maintaining the medicines' orphan status and granting the medicines ten years of market exclusivity.

**Information added on 3 April 2020.

CHMP statistics: March 2020

Positive recommendations on new medicines

Name of medicineAtectura Breezhaler
International non-proprietary name (INN)indacaterol / mometasone furoate
Marketing-authorisation applicantNovartis Europharm Limited
Therapeutic indicationTreatment of asthma
More informationAtectura Breezhaler: Pending EC decision (updated on 03/04/2020)

 

Name of medicineBemrist Breezhaler
INNindacaterol / mometasone furoate
Marketing-authorisation applicantNovartis Europharm Limited
Therapeutic indicationTreatment of asthma
More informationBemrist Breezhaler: Pending EC decision (updated on 03/04/2020)

 

Name of medicineFluad Tetra
Common nameinfluenza vaccine (surface antigen, inactivated, adjuvanted)
Marketing-authorisation applicantSeqirus Netherlands B.V.
Therapeutic indicationProphylaxis against influenza
More informationFluad Tetra: Pending EC decision

 

Name of medicinePretomanid FGK
INNpretomanid
Marketing-authorisation applicantFGK Representative Service GmbH
Therapeutic indicationTreatment of tuberculosis in combination with bedaquiline and linezolid
More informationPretomanid FGK: Pending EC decision

 

Name of medicineSarclisa
INNisatuximab
Marketing-authorisation applicantsanofi-aventis groupe
Therapeutic indicationTreatment of multiple myeloma
More informationSarclisa: Pending EC decision

 

Name of medicineZeposia
INNozanimod
Marketing-authorisation applicantCelgene Europe BV
Therapeutic indicationTreatment of adult patients with relapsing remitting multiple sclerosis with active disease
More informationZeposia: Pending EC decision

 

Name of medicineZolgensma
INNonasemnogene abeparvovec
Marketing-authorisation applicantAveXis EU Limited
Therapeutic indicationTreatment of spinal muscular atrophy
More informationZolgensma: Pending EC decision
Press releaseNew gene therapy to treat spinal muscular atrophy (corrected)

 

Positive recommendation on new biosimilar medicine

Name of medicineNepexto
INNetanercept
Marketing-authorisation applicantMylan IRE Healthcare Limited
Therapeutic indicationTreatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis, non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis
More informationNepexto: Pending EC decision

 

Positive recommendations on extensions of indications

Name of medicineAdcetris
INNbrentuximab vedotin
Marketing-authorisation holderTakeda Pharma A/S
More informationAdcetris: Pending EC decision

 

Name of medicineCosentyx
INNsecukinumab
Marketing-authorisation holderNovartis Europharm Limited
More informationCosentyx: Pending EC decision

 

Name of medicineIntelence
INNetravirine
Marketing-authorisation holderJanssen-Cilag International NV
More informationIntelence: Pending EC decision

 

Name of medicineJorveza
INNbudesonide
Marketing-authorisation holderDr. Falk Pharma GmbH
More informationJorveza: Pending EC decision

 

Name of medicineKineret
INNanakinra
Marketing-authorisation holderSwedish Orphan Biovitrum AB (publ)
More information

 

Name of medicineRuconest
INNconestat alfa
Marketing-authorisation holderPharming Group N.V.
More informationRuconest: Pending EC decision

 

Public-health recommendations

Name of medicineDirect Oral Anticoagulants (DOAC)
INNapixaban, dabigatran etexilate and rivaroxaban
More informationNo change is needed in use of direct oral anticoagulants following EMA-funded study

 

Name of medicineFosfomycin-containing medicinal products
INNfosfomycin calcium, fosfomycin disodium, fosfomycin sodium, fosfomycin trometamol
More informationRecommendations to restrict use of fosfomycin antibiotics

 

Name of medicineMethocarbamol / paracetamol-containing medicinal products
INNmethocarbamol / paracetamol
More informationBenefits of medicines containing combination of methocarbamol and paracetamol continue to outweigh risks

 

Outcome of arbitration procedure

Withdrawal of initial marketing authorisation application

Name of medicineDoxorubicin Hydrochloride Tillomed
INNdoxorubicin
Marketing-authorisation applicantLaboratorios Tillomed Spain S.L.U.
More informationDoxorubicin Hydrochloride Tillomed: Withdrawn application

 

Name of medicineRituximab Mabion
INNrituximab
Marketing-authorisation applicantMabion Spolka Akcyjna
More information

Rituximab Mabion: Withdrawn application

Rituximab Mabion: Withdrawn application

 

How useful was this page?

Add your rating
Average
1 rating
1 rating